On Jul. 25, 2024, Pfizer announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX®…
On Apr. 26, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved BEQVEZ™ (fidanacogene…
On Jan. 15, 2024, CSL announced that Swissmedic had authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene…
On Dec. 10, 2022, CSL announced data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb)…
On Nov. 22, 2022, the U.S. Food and Drug Administration approved the investigational gene therapy etranacogene dezaparvovec or…